Return of the SPAC? Bihua Chen and Cormorant go for round two after MoonLake success
19 Jan 2024
AcquisitionIPOImmunotherapy
Blank check companies are largely dead and gone, but Bihua Chen and her life sciences investment firm Cormorant are back with a second special purpose acquisition company after successfully combining their first with MoonLake Immunotherapeutics.
Chen and Cormorant filed for a $100 million initial public offering for their SPAC, named Helix Acquisition Corp. II, on Thursday night. It plans to list on the Nasdaq as $HLXB and raise as much as $115 million if underwriters exercise their over-allotment option.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.